Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | GLS | O94925 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | FPR3 | P25089 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3152782 | 0.82 | GAA (0.41) | GAAALDH1A1KDM4EHTTTSHR | |
| SCHEMBL15747082 | 0.80 | KDM4E (0.38) | GAAALDH1A1KDM4EHTTTSHR | |
| SCHEMBL9608890 | 0.78 | GAA (0.44) | GAAALDH1A1KDM4EGLAMAPT | |
| SCHEMBL4207109 | 0.77 | KCNH2 (0.38) | GAAALDH1A1KDM4EHTTTSHR | |
| SCHEMBL21768349 | 0.76 | GAA (0.43) | GAAALDH1A1KDM4EHTTGLA | |
| SCHEMBL25825665 | 0.76 | GAA (0.44) | GAAALDH1A1KDM4ETSHRGLA | |
| SCHEMBL15746137 | 0.75 | GAA (0.42) | GAAALDH1A1KDM4EGLAMAPT | |
| SCHEMBL27111156 | 0.75 | GAA (0.42) | GAAALDH1A1KDM4EGLAMAPT | |
| SCHEMBL3147328 | 0.72 | GAA (0.40) | GAAALDH1A1KDM4EGLAMAPT | |
| SCHEMBL1030394 | 0.72 | GAA (0.44) | GAAALDH1A1KDM4EGLAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115143-B2 | Substituted indole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140148450-A1 | NOVEL SUBSTITUTED INDOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-29 | — | — | US | disclosed |
| EP-2013209-B1 | PYRAZOLO-TETRAHYDROPYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-19 | — | — | EP | disclosed |
| EP-2013209-B1 | PYRAZOLO-TETRAHYDROPYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-7834028-B2 | insomnia or eating disorders such as anorexia; 2-{1-Ethyl-4-[2-(2-fluoro-5-trifluoromethyl-phenyl)-ethyl]-3-methyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-N-methyl-2-phenyl-acetamide for example | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-11-16 | — | — | US | disclosed |
| US-7834028-B2 | insomnia or eating disorders such as anorexia; 2-{1-Ethyl-4-[2-(2-fluoro-5-trifluoromethyl-phenyl)-ethyl]-3-methyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-N-methyl-2-phenyl-acetamide for example | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-11-16 | — | — | US | disclosed |
| US-7834028-B2 | insomnia or eating disorders such as anorexia; 2-{1-Ethyl-4-[2-(2-fluoro-5-trifluoromethyl-phenyl)-ethyl]-3-methyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-N-methyl-2-phenyl-acetamide for example | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-11-16 | — | — | US | disclosed |
| CN-101432285-A | Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-13 | — | — | CN | disclosed |
| US-20090099228-A1 | PYRAZOLO-TETRAHYDRO PYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-04-16 | — | — | US | disclosed |
| US-20090099228-A1 | PYRAZOLO-TETRAHYDRO PYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-04-16 | — | — | US | disclosed |
| US-20090099228-A1 | PYRAZOLO-TETRAHYDRO PYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-04-16 | — | — | US | disclosed |
| EP-2013209-A2 | PYRAZOLO-TETRAHYDROPYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007122591-A2 | PYRAZOLO-TETRAHYDRO PYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007122591-A2 | PYRAZOLO-TETRAHYDRO PYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148450-A1 | NOVEL SUBSTITUTED INDOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APP | GAA 326/4885ALDH1A1 1525/4885KDM4E 2161/4885 |
| US-20090099228-A1 | PYRAZOLO-TETRAHYDRO PYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | GAA 4476/4885ALDH1A1 3242/4885KDM4E 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.